Amaia Exposito-Rodriguez

Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer.

Journal: Quantitative imaging in medicine and surgery

Published: October 14, 2024

Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

Journal: Endocrine

Published: February 22, 2023

Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.

Journal: Langenbeck's archives of surgery

Published: December 13, 2021

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: September 03, 2021

Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer.

Journal: Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

Published: March 01, 2021

Sentinel lymph node biopsy in papillary thyroid cancer: Accuracy and application in clinical practice.

Journal: Cirugia espanola

Published: February 26, 2021

Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.

Journal: Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

Published: April 03, 2019

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?

Journal: Cirugia espanola

Published: December 18, 2017

Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer.

Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer.

Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.

Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.

Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer.

Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer.

Sentinel lymph node biopsy in papillary thyroid cancer: Accuracy and application in clinical practice.

Sentinel lymph node biopsy in papillary thyroid cancer: Accuracy and application in clinical practice.

Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.

Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?

Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.

Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively.